BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 Aug 2024 10:17:26 By NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

28 Aug 2024 09:45:07 By NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

26 Aug 2024 09:45:03 By NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

23 Aug 2024 10:45:41 By NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 Aug 2024 09:45:50 By NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 Aug 2024 09:45:08 By NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 07:00:24 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 07:00:47 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 Jul 2024 09:56:40 By NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 Jul 2024 07:00:09 By Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2024 07:00:06 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 07:00:59 By Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 Jun 2024 04:00:13 By Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 May 2024 07:00:53 By Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

07 May 2024 07:00:22 By Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

06 May 2024 07:00:00 By Nasdaq GlobeNewswire